Scarica l'app Stockscreener
16.57
2.35%
0.38
Pre-mercato:
16.56
-0.01
-0.06%
Precedente Chiudi:
$16.19
Aprire:
$16.265
Volume 24 ore:
325.66K
Relative Volume:
0.49
Capitalizzazione di mercato:
$735.37M
Reddito:
$9.00M
Utile/perdita netta:
$-80.61M
Rapporto P/E:
-7.3868
EPS:
-2.2432
Flusso di cassa netto:
$-82.35M
1 W Prestazione:
-5.91%
1M Prestazione:
-11.49%
6M Prestazione:
+200.73%
1 anno Prestazione:
+343.05%
Intervallo 1D:
$16.27
$17.46
Intervallo di 1 settimana:
$15.77
$18.65
Portata 52W:
$3.635
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.57 | 718.51M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Needham | Buy |
| 2026-02-25 | Iniziato | Oppenheimer | Outperform |
| 2026-02-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2026-01-27 | Iniziato | Piper Sandler | Overweight |
| 2025-12-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-12-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-21 | Iniziato | Citigroup | Buy |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-21 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioage Labs Inc Borsa (BIOA) Ultime notizie
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - Bitget
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
Weekly Trades: Is BioAge Labs Inc in accumulation or distribution phaseMarket Activity Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN
Fund Flows: Can BioAge Labs Inc expand its profit margins2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself — And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells - Baystreet.ca
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore
What date does BioAge Labs, Inc.'s (BIOA) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK
BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com South Africa
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan
Risk Hedge: How do insiders feel about BioAge Labs IncWeekly Profit Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
BIOA PE Ratio & Valuation, Is BIOA Overvalued - Intellectia AI
Short Covering: Can BioAge Labs Inc lead its sector in growthWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Paul Rubin reports three 7,433-share sales (BIOA) in Form 144 - Stock Titan
BioAge Labs, Inc. (BIOA) stock price, news, quote and history - Yahoo Finance UK
BioAge Labs (NASDAQ:BIOA) Shares Up 8.7%Here's Why - MarketBeat
BGE-102 Data Inspires Confidence for BioAge Labs (BIOA) - insidermonkey.com
Market Trends: Can BioAge Labs Inc expand its profit marginsTreasury Yields & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Street Watch: Whats the beta of BioAge Labs Inc stock2026 EndofMonth & Weekly Top Stock Performers List - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap UpStill a Buy? - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com
BioAge Labs (NASDAQ:BIOA) Coverage Initiated at Needham & Company LLC - MarketBeat
Needham Initiates BioAge Labs at Buy With $50 Price Target - marketscreener.com
Needham Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $50 - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating - TipRanks
BioAge Highlights BGE-102 Progress and Financial Strength - The Globe and Mail
Earnings Update: How correlated is BioAge Labs Inc to the S P5002026 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
Price Action: Can BioAge Labs Inc. lead its sector in growth2026 Review & High Accuracy Trade Alerts - baoquankhu1.vn
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 - Investing.com
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Form 10-K BioAge Labs, Inc. For: Dec 31 - StreetInsider
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.06%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):